Browsing: Clinical > Antimicrobial Resistance
Ahead of the Call to Action on Antimicrobial Resistance in Berlin the UK’s Chief Medical Officer, Sally Davies, spoke about the need to ensure antimicrobial resistance stays on the political agenda, and the role of the individual in achieving this, at Antibiotic Research UK’s annual lecture.
Silver nanoparticles have long been used as potent antibacterial agents. However, toxicity concerns of silver nanoparticles have limited their successful clinical applications. This research reports a simple and cost-effective method for the synthesis of nickel-prussian blue@silver nanocomposites.
In this editorial the authors discuss the current methods for identifying carbapenemase producers and give a future perspective, highlighting the imemdiate action required to tackle the broader problem of antimicrobial resistance.
Julie Kaiser discusses the findings and implications of a recent study published in PNAS modeling the sequence of events that increases the risk of colonization and infection with multidrug-resistant (MDR) bacteria.
The spread of a single multi-drug resistant Plasmodium falciparum lineage to south Vietnam has caused alarm after worrying treatment failure rates. Researchers suggest this presents a serious concern for malaria control efforts.
In this exclusive piece, the authors look at antihelmintics in both animal and human health – arguing that evolution of resistance necessitates drug development.
In this review, the authors consider phage therapy that can be used for treating bacterial infections in humans, domestic animals and even biocontrol in foods. They also explore common practice – both experimental and, in certain regions of the world, clinical – of mixing therapeutic phages into cocktails consisting of multiple virus types.
In this column author, Julie Kaiser, explores two recent studies that have highlighted how prior antibiotic exposure can influence the later occurrence of resistance to other antibiotics in Pseudomonas aeruginosa.